Privium Fund Management B.V. Buys 1,920 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Privium Fund Management B.V. increased its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 42.7% during the 2nd quarter, Holdings Channel.com reports. The fund owned 6,420 shares of the company’s stock after purchasing an additional 1,920 shares during the quarter. Privium Fund Management B.V.’s holdings in Krystal Biotech were worth $1,140,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of KRYS. Charles Schwab Investment Management Inc. grew its position in Krystal Biotech by 2.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 185,038 shares of the company’s stock worth $22,956,000 after acquiring an additional 5,258 shares during the last quarter. E Fund Management Co. Ltd. grew its position in Krystal Biotech by 21.9% during the 4th quarter. E Fund Management Co. Ltd. now owns 4,495 shares of the company’s stock worth $558,000 after acquiring an additional 808 shares during the last quarter. TimesSquare Capital Management LLC grew its position in Krystal Biotech by 103.6% during the 4th quarter. TimesSquare Capital Management LLC now owns 250,470 shares of the company’s stock worth $31,073,000 after acquiring an additional 127,435 shares during the last quarter. BNP Paribas Financial Markets grew its position in Krystal Biotech by 34.7% during the 4th quarter. BNP Paribas Financial Markets now owns 39,072 shares of the company’s stock worth $4,847,000 after acquiring an additional 10,057 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Krystal Biotech by 5.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 550,806 shares of the company’s stock worth $68,337,000 after acquiring an additional 30,169 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on KRYS. Citigroup reiterated a “neutral” rating and issued a $204.00 price objective (up previously from $195.00) on shares of Krystal Biotech in a report on Tuesday, August 6th. HC Wainwright increased their price objective on Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a report on Thursday. Evercore ISI increased their price objective on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. Finally, Chardan Capital increased their price objective on Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, August 5th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $190.22.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the transaction, the insider now owns 1,525,882 shares in the company, valued at $268,189,020.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 14.10% of the stock is owned by company insiders.

Krystal Biotech Stock Performance

Shares of KRYS traded down $0.10 on Friday, reaching $195.12. The stock had a trading volume of 202,918 shares, compared to its average volume of 246,171. The firm has a market capitalization of $5.61 billion, a price-to-earnings ratio of 104.34 and a beta of 0.84. The company has a 50-day simple moving average of $194.04 and a 200-day simple moving average of $173.84. Krystal Biotech, Inc. has a 12-month low of $93.95 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.03. The business had revenue of $70.28 million during the quarter, compared to analysts’ expectations of $65.27 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The firm’s quarterly revenue was up 70283900.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.25) earnings per share. On average, analysts expect that Krystal Biotech, Inc. will post 3.13 EPS for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).